216 related articles for article (PubMed ID: 27076168)
1. Peptide-Based Cancer Vaccine Strategies and Clinical Results.
Schneble E; Clifton GT; Hale DF; Peoples GE
Methods Mol Biol; 2016; 1403():797-817. PubMed ID: 27076168
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant HER2/neu peptide cancer vaccines in breast cancer.
Clifton GT; Mittendorf EA; Peoples GE
Immunotherapy; 2015; 7(11):1159-68. PubMed ID: 26567563
[TBL] [Abstract][Full Text] [Related]
3. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
4. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
Parmiani G; Castelli C; Dalerba P; Mortarini R; Rivoltini L; Marincola FM; Anichini A
J Natl Cancer Inst; 2002 Jun; 94(11):805-18. PubMed ID: 12048268
[TBL] [Abstract][Full Text] [Related]
6. Peptide vaccines in breast cancer: The immunological basis for clinical response.
Peres Lde P; da Luz FA; Pultz Bdos A; Brígido PC; de Araújo RA; Goulart LR; Silva MJ
Biotechnol Adv; 2015 Dec; 33(8):1868-77. PubMed ID: 26523780
[TBL] [Abstract][Full Text] [Related]
7. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
8. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
9. [Epitope peptide vaccine with oncoantigen for cancer and its biomarker].
Hazama S; Maeda K; Oka M
Nihon Rinsho; 2012 Dec; 70(12):2189-93. PubMed ID: 23259395
[TBL] [Abstract][Full Text] [Related]
10. Multipeptide vaccination in cancer patients.
Pilla L; Rivoltini L; Patuzzo R; Marrari A; Valdagni R; Parmiani G
Expert Opin Biol Ther; 2009 Aug; 9(8):1043-55. PubMed ID: 19591629
[TBL] [Abstract][Full Text] [Related]
11. Development of tumour peptide vaccines: From universalization to personalization.
Ma M; Liu J; Jin S; Wang L
Scand J Immunol; 2020 Jun; 91(6):e12875. PubMed ID: 32090366
[TBL] [Abstract][Full Text] [Related]
12. Designing therapeutic cancer vaccines by mimicking viral infections.
Sultan H; Fesenkova VI; Addis D; Fan AE; Kumai T; Wu J; Salazar AM; Celis E
Cancer Immunol Immunother; 2017 Feb; 66(2):203-213. PubMed ID: 27052572
[TBL] [Abstract][Full Text] [Related]
13. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome.
Voskens CJ; Strome SE; Sewell DA
Curr Mol Med; 2009 Aug; 9(6):683-93. PubMed ID: 19689295
[TBL] [Abstract][Full Text] [Related]
14. Overview of mimotopes and related strategies in tumor vaccine development.
Zhao L; Liu Z; Fan D
Expert Rev Vaccines; 2008 Dec; 7(10):1547-55. PubMed ID: 19053210
[TBL] [Abstract][Full Text] [Related]
15. [WT1 peptide cancer vaccine].
Sugiyama H
Nihon Rinsho; 2017 Feb; 75(2):263-269. PubMed ID: 30562862
[TBL] [Abstract][Full Text] [Related]
16. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
18. Peptide-Based Treatment: A Promising Cancer Therapy.
Xiao YF; Jie MM; Li BS; Hu CJ; Xie R; Tang B; Yang SM
J Immunol Res; 2015; 2015():761820. PubMed ID: 26568964
[TBL] [Abstract][Full Text] [Related]
19. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
Naylor PH; Hernandez KE; Nixon AE; Brandwein HJ; Haas GP; Wang CY; Hadden JW
Vaccine; 2010 Oct; 28(43):7054-62. PubMed ID: 20708999
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
Benavides LC; Sears AK; Gates JD; Clifton GT; Clive KS; Carmichael MG; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2011 Feb; 10(2):201-10. PubMed ID: 21332269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
